Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 3.

Hauschild, Axel; Dummer, Reinhard; Schadendorf, Dirk; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Lesimple, Thierry; Plummer, Ruth; Dasgupta, Kohinoor; Haas, Tomas; Shilkrut, Mark; Gasal, Eduard; Kefford, Richard; Kirkwood, John M; Long, Georgina V (2018). Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma. Journal of Clinical Oncology:JCO1801219.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Long, Georgina V; Weber, Jeffrey S; Larkin, James; Atkinson, Victoria; Grob, Jean-Jacques; Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Márquez-Rodas, Ivan; McNeil, Catriona; Schmidt, Henrik; Briscoe, Karen; Baurain, Jean-François; Hodi, F Stephen; Wolchok, Jedd D (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3(11):1511.

This list was generated on Fri Dec 14 10:41:27 2018 CET.